Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations

• 資料種別: 記事
• タイトル: Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations
• 著者・編者: Tomofumi Moriyama; Yosuke Nakayama; Mikiko Soejima
• 出版事項: 日本 : Springer Nature
• 出版年月日等: 2020-11-03
• 出版年（W3CDTF）: 2020-11-03
• タイトル（掲載誌）: Clinical and experimental nephrology : official publication of the Japanese Society of Nephrology
• 巻号年月日等（掲載誌）: 25(3)
• 掲載巻: 25(3)
• ISSN（掲載誌）: 1437-7799
• ISSN-L（掲載誌）: 1437-7799
• 本文の言語コード: eng
• DOI: 10.1007/s10157-020-01988-4; https://doi.org/10.1007/s10157-020-01988-4
• 国立国会図書館永続的識別子: info:ndljp/pid/11851726; https://dl.ndl.go.jp/pid/11851726
• コレクション（共通）: 障害者向け資料
• コレクション（障害者向け資料：レベル1）: テキストデータ
• コレクション（個別）: 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他; https://dl.ndl.go.jp/collections/B00035
• 収集根拠: オンライン資料収集制度
• 受理日（W3CDTF）: 2021-10-28T02:09:55+09:00
• 保存日（W3CDTF）: 2021-09-30
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: 国立国会図書館内限定公開
• デジタル化資料送信: 図書館・個人送信対象外
• 遠隔複写可否（NDL）: 可
• 掲載誌（URI）: https://link.springer.com/article/10.1007/s10157-020-01988-4
• 掲載誌（国立国会図書館永続的識別子）: info:ndljp/pid/11851721; https://dl.ndl.go.jp/pid/11851721
• 連携機関・データベース: 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

• 要約等: コレクション : 国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他
• DOI: 10.1007/s10157-020-01988-4; https://doi.org/10.1007/s10157-020-01988-4
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（URI）: http://id.ndl.go.jp/digimeta/11851726; https://dl.ndl.go.jp/pid/11851726; http://link.springer.com/content/pdf/10.1007/s10157-020-01988-4.pdf; http://link.springer.com/article/10.1007/s10157-020-01988-4/fulltext.html
• 参照: Protocol for the nationwide registry of patients with polycystic kidney disease: japanese national registry of PKD (JRP); https://cir.nii.ac.jp/crid/1360869854339244928
• 参照: Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial; https://cir.nii.ac.jp/crid/1360283695000186624; An autopsy case of subarachnoid hemorrhage due to ruptured cerebral aneurysm associated with polycystic kidney disease caused by a novel PKD1 mutation; https://cir.nii.ac.jp/crid/1360285707135663616; Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease; https://cir.nii.ac.jp/crid/1360292619703127168; Technical Evaluation: Identification of Pathogenic Mutations in PKD1 and PKD2 in Patients with Autosomal Dominant Polycystic Kidney Disease by Next-Generation Sequencing and Use of a Comprehensive New Classification System; https://cir.nii.ac.jp/crid/1360567187553189888; Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease; https://cir.nii.ac.jp/crid/1360574093989900160; Comparison of phenotypes of polycystic kidney disease types 1 and 2; https://cir.nii.ac.jp/crid/1360574094392866944; Mutations in GANAB , Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease; https://cir.nii.ac.jp/crid/1360855570085784448; Prevalence and Renal Prognosis of Diagnosed Autosomal Dominant Polycystic Kidney Disease in Japan; https://cir.nii.ac.jp/crid/1361137044739477888; Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease; https://cir.nii.ac.jp/crid/1361137044772459520; Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype; https://cir.nii.ac.jp/crid/1361418521330425728; Autosomal dominant polycystic kidney disease; https://cir.nii.ac.jp/crid/1361699994617438976; Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells; https://cir.nii.ac.jp/crid/1362262944774489472; Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease; https://cir.nii.ac.jp/crid/1362262944933397504; Mutation analysis in<i>PKD1</i>of Japanese autosomal dominant polycystic kidney disease patients; https://cir.nii.ac.jp/crid/1362262945773462912; Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate; https://cir.nii.ac.jp/crid/1362825893972197504; Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial; https://cir.nii.ac.jp/crid/1362825896102573952; Management of Cerebral Aneurysms in Autosomal Dominant Polycystic Kidney Disease; https://cir.nii.ac.jp/crid/1363670318260327680; Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial; https://cir.nii.ac.jp/crid/1364233269180457088; Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan; https://cir.nii.ac.jp/crid/1571417126313637248; Faculty Opinions recommendation of Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.; https://cir.nii.ac.jp/crid/1883961342273828736; Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD); https://cir.nii.ac.jp/crid/2051714792006397440
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: 雑誌記事索引データベース; https://ndlsearch.ndl.go.jp; Crossref; https://www.crossref.org; 科学研究費助成事業データベース; https://kaken.nii.ac.jp/ja
• 書誌ID（NDLBibID）: 11851726; http://id.ndl.go.jp/bib/11851726